Thursday, September 29, 2022


Biotechnology News Magazine

Biotron BIT225 Covid-19 Human Study Commenced

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

The Directors of Biotron Limited (‘Biotron’ or ‘the Company’) are pleased to advise that the Company has commenced a human trial of its lead antiviral drug BIT225 against COVID-19.

The COVID-19 trial of BIT225 has been of approved as a sub-study in the ongoing Phase 2 BIT225-010 HIV-1 clinical trial (ACTRN12621000937819) currently in progress at sites in Thailand.

The COVID-19 sub-study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok which is responsible for ethics approval at the HIV-NAT site where the trial is underway.

Twenty-seven people have been enrolled into the BIT225-010 HIV-1 clinical trial. Any of these people who are diagnosed with symptomatic COVID-19 infection during the six-month treatment period will be enrolled in the COVID-19 sub-study. SARS-CoV-2 viral load and clinical symptoms will be intensively assessed over a 28-day period.

Participants included in the COVID-19 sub-study will continue on the HIV-1 trial throughout the sub-study and after the sub-study’s conclusion. The BIT225-010 study’s randomisation and blind will be maintained throughout the COVID-19 sub-study. Primary and secondary objectives of the trial remain unchanged from those previously announced on 1 Nov 2021. The changes in SARS-CoV-2 viral loads and COVID-related symptoms have been incorporated as exploratory objectives.

BIT225 has demonstrated both antiviral and favourable immunomodulatory effect in its current development for HIV-1 (ASX announcements 28 September 2018, 28 Novovember 2018, 3 December 2019, 12 March 2020) and has recently demonstrated both antiviral, immune modulatory and clinical benefit against SARS-CoV-2 in an accepted murine model of disease (ASX announcements 25 November 2021, 17 March 2022, 2 May 2022).

The sub-study will follow the same timetable as the parent HIV-1 trial. As previously advised (ASX announcement 23 August 2022) the BIT225-010 trial is expected to conclude in February 2023, with preliminary results anticipated in mid-2023.

Biotron’s Managing Director, Dr. Michelle Miller said:

“We are very pleased to be able to incorporate an assessment of BIT225 against SARS-CoV-2 infection and COVID-19 into our on-going Phase 2 HIV-1 clinical trial. There are minimal additional costs associated with the sub-study and no expected impact on timing of the results of the BIT225-010 trial as it is fully recruited.

The sub-study provides a speedy and cost-effective pathway to explore the potential benefit of BIT225 against SARS-CoV-2 in a high-risk patient population. We look forward to completing the study and reporting results in mid-2023.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine